STAT

OCTOBER 12, 2023

Good morning, everyone, and welcome to another busy day. We are scrambling, in fact, to update our to-do list, schedule online calls, and sort out deadlines. To cope, we are quaffing several cups of stimulation, of course. Our choice today is maple bourbon. Meanwhile, here is the latest selection of interesting items for you to peruse.

102

102

Pharmacy Times

DECEMBER 9, 2022

The decision is updated from a 2017 recommendation to screen people for obstructive sleep apnea, which can lead to daytime sleepiness and other adverse outcomes.

139

139

Pharmacy Times

DECEMBER 21, 2023

The cost of defending license matters and malpractice claim costs have increased over a 5-year period (2017-2022).

132

132

Pharmacy Times

JULY 24, 2024

In April 2017, the drug was approved to treat the slow loss of the ability to walk for symptomatic patients aged 3 and older who had Batten disease.

FDA 122

FDA 122

STAT

JULY 31, 2024

These new additions join 12 other risk factors outlined by the commission, affiliated with University College London, in previous reports on dementia prevention, intervention, and care in 2017 and 2020.

145

145

Pharmacy Times

DECEMBER 22, 2022

Alex Barker founded The Happy PharmD to provide career coaching and career development classes, and since 2017, the company has helped over 1,500 pharmacists.

132

132

STAT

JUNE 6, 2024

Federal officials, medical organizations, and reproductive health advocacy groups have expressed outrage in response to STAT’s recent investigation revealing that women with sickle cell disease have felt pressured into sterilizations as recently as 2017 and 2022.

144

144

Fierce Pharma

MARCH 20, 2024

After Johnson & Johnson last year changed its mind on its 2017 purchase of ap | Idorsia's Tryvio is the first oral anti-hypertensive therapy that uses a new therapeutic mechanism in nearly 40 years, suggesting the dawn of "a new era of endothelin research," the company said.

FDA 122

FDA 122

Pharmacy Times

APRIL 11, 2024

Benralizumab was previously approved by the FDA in 2017 as an add-on maintenance therapy for patients 12 years and older.

FDA 111

FDA 111

Fierce Pharma

APRIL 8, 2024

Many cancer meds approved under the FDA's accelerated approval pathway from 2013 to 2017 didn't improve overall survival after more than five years of follow-up research, the study found. One hallmark of the FDA's accelerated approval pathway is the requirement that medicines prove their benefits in confirmatory trials.

FDA 119

FDA 119

STAT

APRIL 3, 2024

That was until 2017, when he founded a startup called Nucleai. For around 20 years, Avi Veidman spent his days in the Israeli intelligence community, analyzing satellite images. Now, he’s scouring biopsy samples for cancer cells. Nucleai’s technology is not searching out signs of danger.

138

138

pharmaphorum

APRIL 8, 2024

Less than half of the cancer therapies given accelerated approval by the FDA in 2013 to 2017 showed a clinical benefit in a confirmatory trial within the next five years

FDA 110

FDA 110

STAT

MAY 28, 2024

A new investigation, published on Friday in JAMA Network Open , confirmed the link to early deliveries at a massive scale, in a large cohort study capturing over half of the births that occurred in the United States between 1993 and 2017. Its results shed light on the way existing health inequities may be exacerbated by a worsening climate.

140

140

Fierce Pharma

SEPTEMBER 13, 2024

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | The day after Roche gained an FDA approval for its subcutaneous version of cancer drug Tecentriq, the company also scored with a U.S. nod for its under-the-skin formulation of mega-blockbuster multiple sclerosis drug Ocrevus.

FDA 122

FDA 122

STAT

SEPTEMBER 18, 2024

In 2017, at the age of 42, Susan Whitehead was diagnosed with an early form of breast cancer after discovering a lump in her breast. She embarked on a challenging path of treatment, including a recurrence with stage 2 cancer four years later. Susan underwent two lumpectomies, a mastectomy, radiation, and chemotherapy.

Chemotherapy 128

Chemotherapy 128

Fierce Healthcare

APRIL 19, 2024

The company, which launched in 2017, has contracts with four cities for its network of AEDs to improve survival rates of sudden cardiac arrest. Portable defibrillator company Avive Solutions raised $56.5 million in growth equity financing to build out its staff and commercial developments. |

116

116

STAT

APRIL 23, 2024

But the agency noted in a press release that it’s the largest year-over-year update for NIH-funded postdocs since 2017. The 8% pay bump is far short of the increase to $70,000 that was recommended by an NIH working group late last year.

141

141

Fierce Pharma

DECEMBER 6, 2023

In 2017, Daiichi's former subsidiary Plexxikon alleged that Novartis stepped on its Zelboraf patents with its GSK-acquired medicine Tafinlar. After years of back and forth with Daiichi Sankyo over cancer drug patent claims, Novartis has thrown in the towel with a $182 million settlement. |

123

123

STAT

OCTOBER 10, 2024

Nye has previously spoken about the genetic disease, which makes it difficult for people with the condition to control their muscles and often leads to problems with walking and speech, in a documentary released in 2017. He said then that he didn’t have children because of concerns he would pass on the disease to them. 

138

138

Fierce Pharma

JUNE 20, 2024

The revised deal, first established back in July of 2017, will now see Baxter pay Samsung upwards of $223 million for its manufacturing services through end of 2034. On a revised dealmaking spree this year, Korea’s Samsung Biologics is re-tooling its long-running drug manufacturing pact with Baxter Healthcare. |

114

114

STAT

MAY 6, 2024

Abrams, a frequent commentator about vaping in the news media, including CBS This Morning, CNN, and The New Yorker, coordinated extensively with Juul on public messaging in 2017 and 2018, according to company emails.

Documentation 145

Documentation 145

STAT

DECEMBER 4, 2023

“We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year.  His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9 , which promised to cure numerous genetic diseases.

Documentation 145

Documentation 145

STAT

MAY 21, 2024

She was seven months pregnant when the doctor brought it up in April 2017. She sat on the couch in the half-light, blinds shut against the heat. The whole thing made her feel less than, like some essential part of her had been removed. She shouldn’t eat before the operation.

145

145

STAT

MARCH 5, 2024

The first continuous glucose monitor was approved by the FDA in 2017. The sensor will pair with a smartphone app, which will provide blood glucose measurements every 15 minutes. Dexcom has not yet released the price of the device.

FDA 144

FDA 144

STAT

MAY 24, 2023

Over the last few years, Daniel Cleggett Jr. appeared to be living a charmed life.

145

145

STAT

APRIL 11, 2024

In 2017, after receiving reports about the telehealth site, an investigator for the California medical board logged on to Lemonaid using an alias. Ho Anh had just started working at Lemonaid Health when he was caught up in a sting.

138

138

Fierce Pharma

NOVEMBER 7, 2023

Since launching the Regeneron-partnered antibody Dupixent in 2017, Sanofi has relied on the star medicine for sales growth.

Communication 98

Communication 98

Fierce Pharma

JULY 27, 2023

scored a legal win in the insurance case tied to the 2017 "NotPetya" cyberattack, the case is in appeals—again. scored a legal win in the insurance case tied to the 2017 "NotPetya" cyberattack, the case is in appeals—again. About a month and a half after Merck & Co. That didn't take long.

Insurance 98

Insurance 98

STAT

MARCH 25, 2024

The initial effort to raise and sell chickens without using antibiotics began in 2017 as the company bet consumers would absorb the added expense. Continue to STAT+ to read the full story…

Labelling 138

Labelling 138

STAT

SEPTEMBER 21, 2023

Her mom, Kathy Cronin, lived her life in fear of the disease, an anxiety both her children and her doctors dismissed, until, in the summer of 2017, she developed symptoms that were impossible to ignore.  It took her great-grandfather before she was born and her grandmother when she was 6 years old.

145

145

STAT

DECEMBER 8, 2023

In 2017, he was elevated to CEO. Samarth “Sam” Kulkarni has been there from almost the beginning. The former McKinsey partner joined CRISPR Therapeutics in 2015 as its chief business officer. STAT spoke to Kulkarni about how the company reached this point, and where the field of CRISPR-based medicine is going.

137

137

STAT

FEBRUARY 29, 2024

Founded in 2017, HumanFirst maintains a meticulously organized library of digital measurement tools, their underlying evidence, and information about how they have been used in clinical trials.

Pharmaceutical Companies 141

Pharmaceutical Companies Pharmaceutical Companies 141

STAT

JULY 5, 2024

The massive sum spent by AbbVie, the maker of the mega blockbuster anti-inflammatory drug Humira, is the most a pharmaceutical company has spent on marketing to doctors since such data became available in 2017.

Pharmaceutical Companies 136

Pharmaceutical Companies Pharmaceutical Companies Hospitals 136

STAT

OCTOBER 31, 2024

Between 2017 and 2021, regulators in the U.S. Of 104 reports of supply chain issues with dozens of drugs, meaningful shortages were 40% less likely to occur in Canada than in the U.S., a new study found, and the difference was largely attributed to the approach taken by the Canadian government to the problem.

FDA 137

FDA 137

STAT

APRIL 7, 2024

years after accelerated approval for cancer drugs to be pulled from the market if follow-up trials didn’t show a benefit; by 2017, that timing dropped to 3.6 The study also found evidence that drugs granted accelerated approval, meant to be a temporary designation, are spending less time in limbo. In 2013, it took an average of 9.9

FDA 145

FDA 145

STAT

JUNE 17, 2024

From 2017 to 2020, the company sold nearly 8,000 devices with the fake component. Under CEO Laura Perryman’s leadership, the company warped the design of their devices to earn more reimbursement money from insurers, resulting in unnecessary plastic parts that allowed doctors to claim around $18,000 more than they previously could.

Insurance 135

Insurance FDA 135

Fierce Pharma

MAY 31, 2023

After an investigation that dates back to 2017, four former Novartis executives and a Greek politician were cleared of bribery charges. After a yearslong investigation involving politicians and medical professionals alike, Novartis is looking to close the books on its Greek bribery imbroglio.

111

111